The non-competitive NMDA antagonist ketamine is an old drug that traditionally has been used as an anesthetic with unique properties dissociative anesthesia. More recently, it has been repeatedly shown that a single dose of ketamine is able to quickly relieve major depressive symptoms (including suicidal thoughts) in severely affected patients. This effect appears to be transient (the effect lasts less than one week), robust and reproducible, although several questions on its clinical use remain to be addressed. We therefore propose to test the hypothesis that ketamine and/or its metabolites acutely enhance serotoninergic (5HT) transmission by either modulating afferent synaptic transmission onto serotonin neurons of the dorsal raphe or c...
Major depressive disorder (MDD) is a devitalizing psychiatric condition with a lifetime prevalence o...
Major depressive disorder (MDD) is a devitalizing psychiatric condition with a lifetime prevalence o...
In the search for new drug targets, that may help point the way to develop fast-acting treatments fo...
It has been shown repeatedly that the old drug ketamine is able to induce a rapid (within hours to ...
Ketamine is a clinical anesthetic and antidepressant. Although ketamine is a known NMDA receptor ant...
The dissociative anaesthetic, ketamine, is commonly known as a NMDA receptor channel blocker. Howeve...
A partial account of the present study was presented at the 29th Congress of the European College of...
Ketamine is a non-competitive NMDA antagonist that has been shown to have antidepressant properties ...
© 2016, the American Society of Anesthesiologists, Inc. Wolters Kluwer Health, Inc. All Rights Reser...
Trabajo presentado en Barcelona Computational, Cognitive and Systems Neuroscience (BARCCSYN), celebr...
A growing body of literature has demonstrated the potential for ketamine in the treatment of major d...
A growing body of literature has demonstrated the potential for ketamine in the treatment of major d...
A single i.v. infusion of ketamine, classified as an N-methyl-d-aspartate (NMDA) receptor antagonist...
A growing body of literature has demonstrated the potential for ketamine in the treatment of major d...
A growing body of literature has demonstrated the potential for ketamine in the treatment of major d...
Major depressive disorder (MDD) is a devitalizing psychiatric condition with a lifetime prevalence o...
Major depressive disorder (MDD) is a devitalizing psychiatric condition with a lifetime prevalence o...
In the search for new drug targets, that may help point the way to develop fast-acting treatments fo...
It has been shown repeatedly that the old drug ketamine is able to induce a rapid (within hours to ...
Ketamine is a clinical anesthetic and antidepressant. Although ketamine is a known NMDA receptor ant...
The dissociative anaesthetic, ketamine, is commonly known as a NMDA receptor channel blocker. Howeve...
A partial account of the present study was presented at the 29th Congress of the European College of...
Ketamine is a non-competitive NMDA antagonist that has been shown to have antidepressant properties ...
© 2016, the American Society of Anesthesiologists, Inc. Wolters Kluwer Health, Inc. All Rights Reser...
Trabajo presentado en Barcelona Computational, Cognitive and Systems Neuroscience (BARCCSYN), celebr...
A growing body of literature has demonstrated the potential for ketamine in the treatment of major d...
A growing body of literature has demonstrated the potential for ketamine in the treatment of major d...
A single i.v. infusion of ketamine, classified as an N-methyl-d-aspartate (NMDA) receptor antagonist...
A growing body of literature has demonstrated the potential for ketamine in the treatment of major d...
A growing body of literature has demonstrated the potential for ketamine in the treatment of major d...
Major depressive disorder (MDD) is a devitalizing psychiatric condition with a lifetime prevalence o...
Major depressive disorder (MDD) is a devitalizing psychiatric condition with a lifetime prevalence o...
In the search for new drug targets, that may help point the way to develop fast-acting treatments fo...